{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:53:49Z","timestamp":1794866029664,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progressive multifocal leukoencephalopathy (PML) is a rare but fatal opportunistic infection and mainly occurs in patients with immunosuppressive conditions. Despite the increasing number of patients receiving immunosuppressive treatments, studies on PML are still lacking due to its low prevalence and incidence. We retrospectively reviewed patients diagnosed with PML in two tertiary hospitals in South Korea from 1999 to 2021. Total of 47 PML patients were included. Of 27 patients (57.4%) were diagnosed with human immunodeficiency virus (HIV). Median last follow-up modified Rankin Scale (mRS) score was higher in the non-HIV PML group than that in the HIV group (5 vs. 4, <jats:italic>p<\/jats:italic>\u2009=\u20090.020). Median survival duration was lower in the non-HIV group (184 vs. 1,564\u00a0days). The 1-year and overall mortality rates of PML patients were significantly higher in the non-HIV group than that in HIV group (60.0% vs. 25.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.019; 80.0% vs. 40.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.007). Initial mRS score (HR 1.685, <jats:italic>p<\/jats:italic>\u2009=\u20090.038) and highly active antiretroviral therapy (HAART) in HIV patients (HR 0.374, <jats:italic>p<\/jats:italic>\u2009=\u20090.013) had a significant effect on overall mortality. Our findings suggest that early detection of PML with low mRS score and early initiation of HAART in patients with HIV may improve prognosis.<\/jats:p>","DOI":"10.1038\/s41598-023-41147-9","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:33:48Z","timestamp":1693496028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term prognosis and overall mortality in patients with progressive multifocal leukoencephalopathy"],"prefix":"10.1038","volume":"13","author":[{"given":"Jinnam","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhyup","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Young","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Su","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Sup","family":"Yeom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Goo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"6","key":"41147_CR1","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1212\/NXI.0000000000000618","volume":"6","author":"P Anand","year":"2019","unstructured":"Anand, P., Hotan, G. C., Vogel, A., Venna, N. & Mateen, F. J. Progressive multifocal leukoencephalopathy: A 25-year retrospective cohort study. Neurol. Neuroimmunol. Neuroinflamm. 6(6), e618 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"10","key":"41147_CR2","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1086\/598335","volume":"48","author":"N Khanna","year":"2009","unstructured":"Khanna, N. et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin. Infect. Dis. 48(10), 1459\u20131466 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"41147_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac237","author":"M Joly","year":"2022","unstructured":"Joly, M. et al. Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions. Brain https:\/\/doi.org\/10.1093\/brain\/awac237 (2022).","journal-title":"Brain"},{"issue":"8","key":"41147_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S1474-4422(21)00174-5","volume":"20","author":"I Cortese","year":"2021","unstructured":"Cortese, I. et al. BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: An open-label, single-cohort pilot study. Lancet Neurol. 20(8), 639\u2013652 (2021).","journal-title":"Lancet Neurol."},{"issue":"4","key":"41147_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ana.21630","volume":"65","author":"JR Berger","year":"2009","unstructured":"Berger, J. R. & Houff, S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann. Neurol. 65(4), 367\u2013377 (2009).","journal-title":"Ann. Neurol."},{"issue":"9","key":"41147_CR6","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford, D. B. et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 68(9), 1156\u20131164 (2011).","journal-title":"Arch. Neurol."},{"issue":"4","key":"41147_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan, C. S. & Koralnik, I. J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol. 9(4), 425\u2013437 (2010).","journal-title":"Lancet Neurol."},{"issue":"17","key":"41147_CR8","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I Cortese","year":"2019","unstructured":"Cortese, I. et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 380(17), 1597\u20131605 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"41147_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1086\/595299","volume":"199","author":"FN Engsig","year":"2009","unstructured":"Engsig, F. N. et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: A nationwide cohort study. J. Infect. Dis. 199(1), 77\u201383 (2009).","journal-title":"J. Infect. Dis."},{"issue":"23","key":"41147_CR10","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/bloodadvances.2017008201","volume":"1","author":"EC Neil","year":"2017","unstructured":"Neil, E. C. & DeAngelis, L. M. Progressive multifocal leukoencephalopathy and hematologic malignancies: A single cancer center retrospective review. Blood Adv. 1(23), 2041\u20132045 (2017).","journal-title":"Blood Adv."},{"issue":"1","key":"41147_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/QAI.0b013e31817bec64","volume":"49","author":"V Falc\u00f3","year":"2008","unstructured":"Falc\u00f3, V. et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: Results of an observational multicenter study. J. Acquir. Immune Defic. Syndr. 49(1), 26\u201331 (2008).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"10","key":"41147_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/00002030-199810000-00006","volume":"12","author":"H Albrecht","year":"1998","unstructured":"Albrecht, H. et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 12(10), 1149\u20131154 (1998).","journal-title":"AIDS"},{"issue":"19","key":"41147_CR13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","volume":"338","author":"CD Hall","year":"1998","unstructured":"Hall, C. D. et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N. Engl. J. Med. 338(19), 1345\u201351 (1998).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"41147_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/13550280152537238","volume":"7","author":"MD Geschwind","year":"2001","unstructured":"Geschwind, M. D., Skolasky, R. I., Royal, W. S. & McArthur, J. C. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J. Neurovirol. 7(4), 353\u2013357 (2001).","journal-title":"J. Neurovirol."},{"issue":"10","key":"41147_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40261-016-0433-8","volume":"36","author":"Y Jamilloux","year":"2016","unstructured":"Jamilloux, Y. et al. Treatment of progressive multifocal leukoencephalopathy with mirtazapine. Clin. Drug Investig. 36(10), 783\u2013789 (2016).","journal-title":"Clin. Drug Investig."},{"issue":"14","key":"41147_CR16","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1097\/QAD.0b013e32830a5043","volume":"22","author":"A De Luca","year":"2008","unstructured":"De Luca, A. et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: A multicohort analysis. AIDS 22(14), 1759\u20131767 (2008).","journal-title":"AIDS"},{"issue":"4","key":"41147_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","volume":"19","author":"DB Clifford","year":"2013","unstructured":"Clifford, D. B. et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: Results and exploration of predictors of PML outcomes. J. Neurovirol. 19(4), 351\u2013358 (2013).","journal-title":"J. Neurovirol."},{"issue":"4","key":"41147_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jama.2014.8722","volume":"312","author":"HF G\u00fcnthard","year":"2014","unstructured":"G\u00fcnthard, H. F. et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312(4), 410\u2013425 (2014).","journal-title":"JAMA"},{"issue":"15","key":"41147_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger, J. R. et al. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80(15), 1430\u20131438 (2013).","journal-title":"Neurology"},{"issue":"12","key":"41147_CR20","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/art.24966","volume":"60","author":"ES Molloy","year":"2009","unstructured":"Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 60(12), 3761\u20133765 (2009).","journal-title":"Arthritis Rheum."},{"issue":"2","key":"41147_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10096-013-1941-6","volume":"33","author":"JL Casado","year":"2014","unstructured":"Casado, J. L. et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV\/AIDS patients in the current era. Eur. J. Clin. Microbiol. Infect. Dis. 33(2), 179\u2013187 (2014).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"7","key":"41147_CR22","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1128\/JVI.75.7.3483-3487.2001","volume":"75","author":"IJ Koralnik","year":"2001","unstructured":"Koralnik, I. J., Du Pasquier, R. A. & Letvin, N. L. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J. Virol. 75(7), 3483\u20133487 (2001).","journal-title":"J. Virol."},{"issue":"19","key":"41147_CR23","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","volume":"73","author":"A Marzocchetti","year":"2009","unstructured":"Marzocchetti, A. et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73(19), 1551\u20131558 (2009).","journal-title":"Neurology"},{"issue":"1","key":"41147_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","volume":"17","author":"I Cortese","year":"2021","unstructured":"Cortese, I., Reich, D. S. & Nath, A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat. Rev. Neurol. 17(1), 37\u201351 (2021).","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"41147_CR25","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/ana.26198","volume":"90","author":"R Bernard-Valnet","year":"2021","unstructured":"Bernard-Valnet, R., Koralnik, I. J. & Du Pasquier, R. Advances in treatment of progressive multifocal leukoencephalopathy. Ann. Neurol. 90(6), 865\u2013873 (2021).","journal-title":"Ann. Neurol."},{"issue":"3","key":"41147_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ana.10827","volume":"55","author":"A d'Arminio Monforte","year":"2004","unstructured":"d\u2019Arminio Monforte, A. et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann. Neurol. 55(3), 320\u2013328 (2004).","journal-title":"Ann. Neurol."},{"issue":"Suppl 1","key":"41147_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/13550280390195351","volume":"9","author":"P Cinque","year":"2003","unstructured":"Cinque, P. et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: Study of 43 cases with review of the literature. J. Neurovirol. 9(Suppl 1), 73\u201380 (2003).","journal-title":"J. Neurovirol."},{"issue":"1","key":"41147_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13550280802425467","volume":"15","author":"S Delbue","year":"2009","unstructured":"Delbue, S. et al. JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy. J. Neurovirol. 15(1), 51\u201356 (2009).","journal-title":"J. Neurovirol."},{"issue":"3","key":"41147_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.54.3.743","volume":"54","author":"C Power","year":"2000","unstructured":"Power, C. et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 54(3), 743\u2013746 (2000).","journal-title":"Neurology"},{"key":"41147_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fimmu.2018.00138","volume":"9","author":"EA Mills","year":"2018","unstructured":"Mills, E. A. & Mao-Draayer, Y. Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: A bird\u2019s eye view. Front. Immunol. 9, 138 (2018).","journal-title":"Front. Immunol."},{"issue":"15","key":"41147_CR31","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJMc1415408","volume":"372","author":"T Rosenkranz","year":"2015","unstructured":"Rosenkranz, T., Novas, M. & Terborg, C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N. Engl. J. Med. 372(15), 1476\u20131478 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"41147_CR32","doi-asserted-by":"publisher","first-page":"e34103","DOI":"10.1371\/journal.pone.0034103","volume":"7","author":"C de Andr\u00e9s","year":"2012","unstructured":"de Andr\u00e9s, C. et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One 7(4), e34103 (2012).","journal-title":"PLoS One"},{"key":"41147_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.virol.2014.12.033","volume":"479\u2013480","author":"SM Kahan","year":"2015","unstructured":"Kahan, S. M., Wherry, E. J. & Zajac, A. J. T cell exhaustion during persistent viral infections. Virology 479\u2013480, 180\u2013193 (2015).","journal-title":"Virology"},{"issue":"6","key":"41147_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol. 12(6), 492\u2013499 (2011).","journal-title":"Nat. Immunol."},{"issue":"1","key":"41147_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1146\/annurev-virology-100114-055226","volume":"2","author":"EI Zuniga","year":"2015","unstructured":"Zuniga, E. I., Macal, M., Lewis, G. M. & Harker, J. A. Innate and adaptive immune regulation during chronic viral infections. Annu. Rev. Virol. 2(1), 573\u2013597 (2015).","journal-title":"Annu. Rev. Virol."},{"issue":"16","key":"41147_CR36","doi-asserted-by":"publisher","first-page":"10514","DOI":"10.1128\/JVI.79.16.10514-10527.2005","volume":"79","author":"DG Brooks","year":"2005","unstructured":"Brooks, D. G., Teyton, L., Oldstone, M. B. & McGavern, D. B. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J. Virol. 79(16), 10514\u201310527 (2005).","journal-title":"J. Virol."},{"issue":"4","key":"41147_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S1074-7613(00)80628-7","volume":"9","author":"A Oxenius","year":"1998","unstructured":"Oxenius, A., Zinkernagel, R. M. & Hengartner, H. Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. Immunity 9(4), 449\u2013457 (1998).","journal-title":"Immunity"},{"issue":"9","key":"41147_CR38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"Lundgren, J. D. et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med. 373(9), 795\u2013807 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"41147_CR39","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"C Danel","year":"2015","unstructured":"Danel, C. et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N. Engl. J. Med. 373(9), 808\u2013822 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"41147_CR40","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/01.STR.20.6.828","volume":"20","author":"JM Bamford","year":"1989","unstructured":"Bamford, J. M., Sandercock, P. A., Warlow, C. P. & Slattery, J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 20(6), 828 (1989).","journal-title":"Stroke"},{"issue":"2","key":"41147_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jac\/dki444","volume":"57","author":"SA Shelburne","year":"2006","unstructured":"Shelburne, S. A., Montes, M. & Hamill, R. J. Immune reconstitution inflammatory syndrome: More answers, more questions. J. Antimicrob. Chemother. 57(2), 167\u2013170 (2006).","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41147-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T13:10:27Z","timestamp":1700313027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-41147-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["41147"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-41147-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"assertion":[{"value":"12 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14291"}}